Leerink Partnrs Issues Optimistic Outlook for STOK Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at Leerink Partnrs boosted their Q4 2024 earnings per share (EPS) estimates for Stoke Therapeutics in a report released on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of ($0.53) for the quarter, up from their prior forecast of ($0.54). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.11) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($2.20) EPS and FY2028 earnings at ($1.70) EPS.

A number of other equities analysts have also recently weighed in on STOK. Wedbush reissued an “outperform” rating and set a $17.00 price objective on shares of Stoke Therapeutics in a report on Thursday, July 11th. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, September 11th. Finally, Leerink Partners assumed coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Stoke Therapeutics has an average rating of “Buy” and a consensus price target of $20.83.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $13.00 on Friday. The company’s fifty day moving average price is $13.69 and its 200-day moving average price is $13.70. The firm has a market capitalization of $677.57 million, a price-to-earnings ratio of -5.39 and a beta of 0.97. Stoke Therapeutics has a one year low of $3.35 and a one year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. The company had revenue of $4.83 million for the quarter, compared to the consensus estimate of $3.33 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%.

Insider Transactions at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Large investors have recently added to or reduced their stakes in the company. Quest Partners LLC bought a new stake in Stoke Therapeutics during the second quarter valued at about $29,000. Nisa Investment Advisors LLC grew its position in shares of Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Stoke Therapeutics during the 2nd quarter valued at approximately $123,000. State Board of Administration of Florida Retirement System purchased a new position in Stoke Therapeutics in the 1st quarter worth approximately $141,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after purchasing an additional 1,994 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.